February 28, 2024 · Form 4 insider transaction
Poulton Stuart bought 188,205 shares of KARYOPHARM THERAPEUTICS INC at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.
Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2025.